HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease Patients.

AbstractOBJECTIVE:
To evaluate amyloid-β deposition with 18F-florbetaben (FBB) PET imaging against 11C-PIB PET in cognitive normal controls (NC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) patients.
METHODS:
We recruited 45 subjects (15 in each group of NC, MCI, and mild/moderate AD) who had undergone dynamic 18F-FBB amyloid PET imaging. For comparison study, 17 participants, including six NC, five MCI, and six AD patients, also underwent 11C-PIB PET imaging on separate days. Standardized uptake value ratios (SUVR) were calculated using the cerebellar cortex as the reference region with regions of interest (ROI) manually defined on co-registered CT. Quantitative analysis of mean cortical uptake was calculated using global SUVR. Spearman correlation analysis between MMSE scores and SUVR of 18F-FBB and 11C-PIB images were calculated.
RESULTS:
One (7%) of the 15 NC participants, nine (60%) of 15 MCI patients, and 12 (80%) of 15 AD patients had amyloid-positive lesions on 18F-FBB PET images. In AD patients, global SUVR was significantly higher than those of MCI patients (1.73 ± 0.62 vs. 1.55 ± 0.11, P < 0.001) and NC subjects (1.73 ± 0.62 vs. 1.13 ± 0.43, P < 0.001). In the comparison study, one NC participant, five MCI patients, and five AD patients had amyloid-positive lesions on 11C-PIB PET images. There was a significant linear correlation (r 2 = 0.81, P < 0.001) between 18F-FBB and PIB global SUVR values. MMSE scores had negative correlations with SUVR on 11C-PIB PET (r 1 = -0.650, P = 0.005) or SUVR on 18F-FBB PET (r 2 = -0.754, P < 0.0001).
CONCLUSION:
Our study suggests that 18F-FBB is a useful tracer for the evaluation of amyloid-β deposition in vivo and that global SUVR of 18F-FBB PET might be a reliable tool in the diagnosis of AD.
AuthorsYan Chang, Can Li, Hui Yang, Yue Wu, Baixuan Xu, Jinming Zhang, Ruimin Wang
JournalFrontiers in neuroscience (Front Neurosci) Vol. 14 Pg. 745 ( 2020) ISSN: 1662-4548 [Print] Switzerland
PMID32848542 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Chang, Li, Yang, Wu, Xu, Zhang and Wang.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: